Introduction
============

Acute myeloid leukemia (AML), a type of aggressive hematopoietic stem cell tumor, remains a considerable challenge in the clinical setting due to its high relapse rate ([@b1-ol-0-0-10665],[@b2-ol-0-0-10665]). Lethal infections, bleeding and organ invasion are the main complications of AML ([@b3-ol-0-0-10665]). In the past decades, various studies have suggested that both environmental and genetic factors are important in the occurrence of AML ([@b1-ol-0-0-10665],[@b4-ol-0-0-10665]--[@b6-ol-0-0-10665]). However, the current knowledge of the molecular mechanisms involved in the development of AML is limited, and early diagnosis remains difficult, which may result in delayed therapy. Thus, the identification of the key mechanisms regulating AML management and patient survival may aid in the development of AML-specific targeted therapies ([@b3-ol-0-0-10665]).

Microarray technology is a high-throughput and powerful tool to generate large quantities of data, including mRNA expression and DNA methylation ([@b7-ol-0-0-10665]). The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases are two common public platforms obtaining such data. These microarray results provide an opportunity to use bioinformatics to identify novel targets ([@b8-ol-0-0-10665],[@b9-ol-0-0-10665]). Numerous public databases, including Oncomine ([@b10-ol-0-0-10665]), Gene Expression Profiling Interactive Analysis (GEPIA) ([@b11-ol-0-0-10665]) and UALCAN ([@b12-ol-0-0-10665]), provide several bioinformatic analysis tools, including differential expression, co-expression and comparative analyses, to identify novel tumor biomarkers and potential therapeutic targets through the use of the stored microarray data. Therefore, bioinformatics aid in the investigation of the underlying regulatory networks involved in different types of cancer, and constitute a powerful method of cancer research, including the early diagnosis of cancer, grading and prognostic prediction ([@b8-ol-0-0-10665]).

In the present study, microarray data were downloaded to investigate the hub genes affecting the development of AML from GEO in order to identify AML-associated genes via bioinformatics analysis. The present study further investigated those dysregulated genes at the molecular level and explored the potential candidate genes for prognosis in AML.

Materials and methods
=====================

### Microarray data preprocessing and differentially expressed genes (DEGs) analysis

The original dataset GSE9476, provided by Stirewalt *et al* ([@b13-ol-0-0-10665]), was downloaded, which was based on the GPL96 Affymetrix Human Genome U133A Array platform (Affymetrix; Thermo Fisher Scientific, Inc.). The profiling dataset comprising 26 patients with AML and 10 normal peripheral blood samples was selected for further analysis ([@b13-ol-0-0-10665]). The raw data files were processed using the Affy package in R version 3.3.2 (<https://www.r-project.org/>). The limma package version 3.40.2.2 (<http://www.bioconductor.org/packages/release/bioc/html/limma.html>) was applied to identify the DEGs between AML samples and normal peripheral blood mononuclear cells ([@b12-ol-0-0-10665]). \|Fold-change (FC)\| ≥2 and false discovery rate (FDR) \<0.05 were considered to indicate a statistically significant difference.

### GO and KEGG pathway enrichment analyses

To obtain an insight into the function of the DEGs identified, these DEGs were divided into an upregulated (FC≥2 and FDR\<0.05) and a downregulated group (FC≤-2 and FDR\<0.05). Then, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID; [david.ncifcrf.gov/](david.ncifcrf.gov/)) online tool. FDR\<0.05 was considered to indicate a statistically significant difference.

### Oncomine analysis

The differences in mRNA levels of serine protease inhibitor Kazal-type 2 (SPINK2) between the AML and control samples were evaluated using gene expression array datasets from Oncomine, a public cancer microarray database that is accessible online ([@b10-ol-0-0-10665],[@b14-ol-0-0-10665],[@b15-ol-0-0-10665]). The threshold was established at P\<10^−4^ and FC\>2. In addition, the data type was restricted to mRNA levels only.

### GEPIA analysis

GEPIA possesses key customizable and interactive functions, including profiling plotting, differential expression analysis, patient survival analysis, similar gene detection and dimensionality reduction analysis ([@b11-ol-0-0-10665]). Comprehensive expression analyses using GEPIA greatly facilitate data mining in numerous areas of research, thus contributing to scientific discussions and the identification of novel therapies. The present study employed SPINK2 data into the GEPIA dataset to explore its differential expression and effect on the prognosis of patients with AML.

### UALCAN dataset analysis

UALCAN provides easy access to publicly available cancer transcriptome data (namely, TCGA and MET500 transcriptome sequencing). It allows users to identify biomarkers and to perform *in silico* validations of potential genes of interest. In addition, it can depict gene expression and patient survival information based on gene expression ([@b12-ol-0-0-10665]). In the present study, SPINK2 was included into the UALCAN dataset to explore its effect on the prognosis of patients with AML.

### RNA isolation, reverse transcription and quantitative (RT-q) PCR

Blood samples of 6 healthy donors and 12 patients with AML were collected from the left arm at the Linyi Central Hospital between January 2017 and October 2017. The age range of patients was 16--65 years and the male: Female ratio was 4:8. Blood samples were centrifuged at 1,500 g for 5 min and at 4°C, and the fraction containing blood cells was stored at −80°C for future analyses. All blood cells were lysed using TRIzol^®^ (Invitrogen; Thermo Fisher Scientific, Inc.), and total RNAs were extracted. First strand cDNA synthesis was conducted using 2 µg RNA using the SYBR Premix Ex Taq™ II kit (Takara Biotechnology Co.) complete with SYBR Green reagents (Bio-Rad Laboratories, Inc.). The reverse transcriptase reaction was performed for 60 min at 37°C, followed by 60 min at 42°C. qPCR was performed using a 7900HT real-time PCR system (Thermo Fisher Scientific, Inc.), with the Real-Time SYBR Green PCR Master Mix kit (Promega Corporation). The primers used were as follows: SPINK2, forward 5′-GAGTGGCGCAGGTAACAGAC-3′, reverse, 5′-ACCAAATTGAGGGATCAGAGAG-3′; and GAPDH, forward 5′-TGGTGAAGACGCCAGTGGA-3′ and reverse, 5′-GCACCGTAAGGCTGAGAAC-3′. The qPCR thermocycling conditions were as follows: 95°C for 30 sec, 35 cycles at 95°C for 5 sec, then 60°C for 30 sec. The relative mRNA expression was calculated using the 2^−∆∆Cq^ method ([@b16-ol-0-0-10665]).

### Statistical analysis

A paired t-test was used to determine the statistical significance of the differences between healthy donors and patients with AML. The Kaplan-Meier analysis and log rank were used to assess patient survival rates. In the present study, the cut-off of survival analysis was based on the median of expression level in the GEPIA and UALCAN datasets. Data were presented as the means ± standard deviation. Data were analyzed using SPSS 17.0 (SPSS, Inc.). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### DEGs in AML

In the present study, 26 AML and 10 normal samples were analyzed. Upon preprocessing, 3,700 DEGs (FDR\<0.05; log~2~ FC≥1) were identified, including 1,744 upregulated and 1,956 downregulated genes ([Fig. 1A](#f1-ol-0-0-10665){ref-type="fig"}). The heat map of the top 100 upregulated and downregulated genes is presented in [Fig. 1B](#f1-ol-0-0-10665){ref-type="fig"}.

### GO term enrichment analysis for DEGs

The upregulated and downregulated genes were uploaded into the DAVID dataset to perform GO analysis. As presented in [Table I](#tI-ol-0-0-10665){ref-type="table"}, the most important biological processes (BPs) of overexpressed genes were 'nitrogen compound metabolic process', 'cellular nitrogen compound metabolic process' and 'cellular metabolic process'. For the downregulated genes, BPs were significantly enriched in 'immune response', 'immune system process' and 'defense response' ([Table II](#tII-ol-0-0-10665){ref-type="table"}). For molecular function (MF) terms, upregulated DEGs were enriched in 'RNA binding', 'poly (A) RNA binding' and 'nucleic acid binding' ([Table I](#tI-ol-0-0-10665){ref-type="table"}), while the downregulated DEGs were enriched in 'protein binding', 'binding' and 'anion binding' ([Table II](#tII-ol-0-0-10665){ref-type="table"}). The most significant component functions (CFs) for upregulated DEGs were 'intracellular organelle part', 'membrane-enclosed lumen' and 'organelle part' ([Table I](#tI-ol-0-0-10665){ref-type="table"}), while the most significant CF terms for downregulated DEGs were 'cytosol', 'cytoplasm' and 'cell periphery' ([Table II](#tII-ol-0-0-10665){ref-type="table"}).

### KEGG pathway analysis for DEGs

To gain further insight into the function of the genes in the interaction network, the DAVID database was used to identify the significant pathways associated with DEGs. According to the results of KEGG pathway analysis, upregulated DEGs were significantly enriched in 'metabolic pathways', 'Huntington\'s disease' and 'ribosome' ([Table III](#tIII-ol-0-0-10665){ref-type="table"}). For the downregulated DEGs, the most significant pathways were 'osteoclast differentiation', 'tuberculosis' and 'chemokine signaling pathway' ([Table III](#tIII-ol-0-0-10665){ref-type="table"}).

### SPINK2 expression is elevated in patients with AML

Among all the upregulated genes, SPINK2 ranked first (log~2~ FC, 6.59; FDR, 9.86×10^−8^). To validate the expression level of SPINK2 in AML, 6 healthy individuals and 12 patients with AML were recruited in the present study. qPCR results indicated that the levels of SPINK2 mRNA were significantly increased by 10.11-fold (P=0.028) in patients with AML compared with the healthy controls ([Fig. 2A](#f2-ol-0-0-10665){ref-type="fig"}). The expression level of SPINK2 in the AML samples was validated in the Oncomine and GEPIA datasets. In the GEPIA database, 70 normal individuals and 173 patients with AML were included. The results suggested that the mRNA level of SPINK2 was elevated in patients with AML (P\<0.01; [Fig. 2B](#f2-ol-0-0-10665){ref-type="fig"}). From the Oncomine leukemia dataset of Stegmaier *et al* ([@b14-ol-0-0-10665]), SPINK2 expression was determined to be elevated by 20.21-fold in 9 AML samples compared with the PMBCs of 3 normal samples (P=2.12×10^−5^; [Fig. 2C](#f2-ol-0-0-10665){ref-type="fig"}). The study on leukemia conducted by Haferlach *et al* ([@b15-ol-0-0-10665]) revealed that SPINK2 levels were elevated by 2.86-fold (P=8.15×10^−42^) in 542 AML samples compared with 74 normal samples ([Fig. 2D](#f2-ol-0-0-10665){ref-type="fig"}). Therefore, the high expression of SPINK2 in AML was validated in larger cohorts.

### Upregulated SPINK2 is associated with poor outcomes in patients with AML

The present study validated the effect of SPINK2 on the prognosis of patients with AML using the GEPIA and UALCAN datasets. According to the median expression level of SPINK2, the patients were divided into a high-expression and a low-expression group. The results suggested that patients with high SPINK2 expression had shorter survival time than those with low SPINK2 levels in the GEPIA dataset (hazard ratio, 2.3; P=0.0039; [Fig. 3A](#f3-ol-0-0-10665){ref-type="fig"}). In the UALCAN dataset, 163 patients with AML were analyzed for their expression levels of SPINK2. The Kaplan-Meier analysis demonstrated that patients with high SPINK2 expression had shorter survival time than patients with lower SPINK2 levels (P=0.024; [Fig. 3B](#f3-ol-0-0-10665){ref-type="fig"}).

Discussion
==========

The pathogenesis of AML is heterogeneric and complex ([@b17-ol-0-0-10665]). To improve the outcome of AML treatment, it is important to understand the mechanism of AML ([@b5-ol-0-0-10665],[@b18-ol-0-0-10665]). To detect DEGs in patients with AML, high-throughput platforms for the analysis of gene expression, such as microarrays, are increasingly used to identify novel molecular biomarkers and drug targets for clinical applications. Currently, microarray technology that combines bioinformatics analysis allows the wide exploration of the molecular mechanisms involved in the development and progression of AML. Using this method, Gal *et al* ([@b19-ol-0-0-10665]) compared DEGs of cluster of differentiation (CD) 34^+^ CD38^−^ cells and CD34^+^ CD38^+^ cells using microarrays, and observed that 409 genes were 2-fold overexpressed or downregulated between the two cell populations. Previous focus on the Notch signaling pathway revealed that regulated leukemic stem cell self-renewal could be investigated to identify novel targets for therapy ([@b19-ol-0-0-10665]). Based on microarray data from 163 patients, Metzeler *et al* ([@b20-ol-0-0-10665]) developed a gene signature including an 86-probe set to predict the overall survival rate of patients with AML. When the authors applied the prognostic score in an independent cohort, this continuous score remained a significant predictor for the outcomes of patients with AML ([@b20-ol-0-0-10665]). Therefore, bioinformatics analysis could accelerate our understanding of AML ([@b21-ol-0-0-10665],[@b22-ol-0-0-10665]).

The present study analyzed the gene expression patterns of patients with AML and healthy individuals by computational methods, and identified 1,744 upregulated and 1,956 downregulated genes in patients with AML. GO and KEGG functional enrichment analyses demonstrated that the upregulated genes were mainly associated with metabolic processes, which was in agreement with the results of a previous study ([@b23-ol-0-0-10665]). Furthermore, the genes involved in the immune response and cell surface signaling were downregulated according to our results. Cancer cells are able to avoid the immune response via a number of mechanisms ([@b24-ol-0-0-10665]). Tumor cells escape the immune response either by employing mechanisms to suppress the immune response, or by downregulating the expression of immunogenic molecules ([@b25-ol-0-0-10665]). Controlling the immune system in AML may facilitate the treatment of AML. Notably, the expression level of SPINK2 was the most altered among all the upregulated genes. Further analysis validated the upregulation of SPINK2 in patients with AML from the Oncomine and GEPIA datasets. Analysis further suggested that patients with AML and high expression levels of SPINK2 would have poor outcomes. Therefore, the findings from the present study indicated that SPINK2 may serve an important role in the development of AML.

SPINK2, also known as human seminal plasma inhibitor II, belongs to the SPINK family, which consists of members containing ≥1 conserved Kazal domain composed of 6 cysteine residues ([@b26-ol-0-0-10665]--[@b28-ol-0-0-10665]). The expression of SPINK2 is closely associated with cancer development, and high transcript levels of SPINK2 can be detected in patients with primary cutaneous follicle center cell lymphoma ([@b29-ol-0-0-10665]). SPINK2 serves as a classification marker for lymphoma, as well as a predictive marker of response to cancer therapy. Chen *et al* ([@b30-ol-0-0-10665]) reported that SPINK2 was significantly elevated in the majority of the leukemia cell lines investigated, and served an important role in tumor progression and response to treatment. Hoefnagel *et al* ([@b29-ol-0-0-10665]) proposed a possible interaction between SPINK2 and its currently unknown cancer-associated target proteinase, which appeared to be essential for tumor progression and metastasis. In the present study, patients with AML and high levels of SPINK2 had reduced survival times. Thus, we hypothesize that SPINK2 may serve an important role in the process of AML. However, the molecular mechanism of SPINK2 affecting the tumorigenic process remains unclear. Thus, further functional studies are required to deeply investigate how SPINK2 affects the development of AML.

There are some limitations to the present study. First, the GSE9476 dataset provides the complete data of AML and healthy people, but a larger dataset, including more patients, would be more robust. Of note, the GSE9476 dataset was only used to investigate the DEGs, and so the results from the present study require the analysis of additional datasets in order to be validated. The different expression levels of SPINK2 were validated in the present study by analyzing 70 healthy individuals and 173 patients with AML from the GEPIA database, and by analyzing 542 patients with AML and 74 healthy individuals in the report of leukemia by Haferlach *et al* ([@b15-ol-0-0-10665]). Furthermore, the prognosis of patients with AML were validated by analyzing 106 patients with AML from the GEPIA dataset ([@b11-ol-0-0-10665]) and 163 patients with AML from the UALCAN dataset ([@b12-ol-0-0-10665]). Therefore, despite the limited sample size, the results are credible. Secondly, AML has several subgroups, and the DEGs in patients with different subtypes were not analyzed in the present study. Thirdly, although the upregulated levels of SPINK2 mRNA in the Oncomine dataset were investigated in the present study, the protein levels of SPINK2 were not. Additional AML samples are required to validate these results. Finally, the present study only determined that SPINK2 may contribute to the development of AML; further studies are required that investigate the underlying molecular mechanisms of SPINK2 in the progression of AML.

To conclude, the present study has provided a comprehensive investigation of dysregulated genes involved in the progression of AML. SPINK2 could be regarded as a hub gene in patients with AML, and elevated levels of SPINK2 were associated with the poor prognosis in these patients. However, further molecular biology investigations are needed to confirm the mechanisms of SPINK2 in AML.
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![DEGs in patients with AML. (A) Volcano plot of DEGs. The abscissa and ordinates represent log~2~ FC and -log~10~ FDR value, respectively. The red and green dots correspond to upregulated and downregulated genes, respectively; blue dots correspond to non-DEGs. (B) Heat-map of the top 200 DEGs (100 upregulated and 100 downregulated genes). Red indicates upregulated genes and green indicates downregulated genes. DEGs, differentially expressed genes; AML, acute myeloid leukemia; FDR, false discovery rate; FC, fold change; PBMC, peripheral blood mononuclear cell.](ol-18-03-2877-g00){#f1-ol-0-0-10665}

![SPINK2 expression is elevated in patients with AML. (A) The results of the quantitative PCR suggested that the mRNA levels of SPINK2 were increased by 10.11-fold in 12 patients with AML (P=0.028). (B) In the GEPIA dataset, SPINK2 mRNA expression was elevated in patients with AML (\*P\<0.01). (C) In the study on leukemia conducted by Stegmaier *et al* ([@b14-ol-0-0-10665]), SPINK2 was elevated by 20.21-fold (P=2.12×10^−5^). (D) In the study by Haferlach *et al* ([@b15-ol-0-0-10665]) on leukemia, SPINK2 was increased by 2.86-fold (P=8.15×10^−42^). AML, acute myeloid leukemia; PBMC, peripheral blood mononuclear cells; SPINK2, serine protease inhibitor Kazal-type 2; AML, acute myeloid leukemia; GEPIA, gene expression profiling interactive analysis.](ol-18-03-2877-g01){#f2-ol-0-0-10665}

![Upregulated SPINK2 is associated with the poor prognosis of patients with acute myeloid leukemia. (A) In the GEPIA dataset, patients with high SPINK2 expression had poor outcomes (hazard ratio=2.3, P=0.0039). (B) In the UALCAN dataset, patients with high SPINK2 expression would have shorter survival time than those with lower SPINK2 levels (P=0.024). SPINK2, serine protease inhibitor Kazal-type 2; GEPIA, gene expression profiling interactive analysis.](ol-18-03-2877-g02){#f3-ol-0-0-10665}

###### 

GO Enrichment analysis of upregulated DEGs.

  A, Biological processes                                                                     
  --------------------------- ---------------------------------------------- ---------------- --------------
  GO.0006807                  Nitrogen compound metabolic process            562              5.32×10^−57^
  GO.0034641                  Cellular nitrogen compound metabolic process   537              4.68×10^−56^
  GO.0044237                  Cellular metabolic process                     712              4.33×10^−50^
  GO.0044238                  Primary metabolic process                      719              4.33×10^−50^
  GO.0071704                  Organic substance metabolic process            722              7.52×10^−47^
                                                                                              
  **B, Molecular function**                                                                   
                                                                                              
  **GO ID**                   **Pathway description**                        **Gene count**   **FDR**
                                                                                              
  GO.000723                   RNA binding                                    292              3.36×10^−75^
  GO.0044822                  Poly(A) RNA binding                            249              1.00×10^−73^
  GO.0003676                  Nucleic acid binding                           410              2.01×10^−40^
  GO.1901363                  Heterocyclic compound binding                  520              1.27×10^−36^
  GO.0097159                  Organic cyclic compound binding                523              4.32×10^−36^
                                                                                              
  **C, Component function**                                                                   
                                                                                              
  **GO ID**                   **Pathway description**                        **Gene count**   **FDR**
                                                                                              
  GO.0044446                  Intracellular organelle part                   759              5.24×10^−84^
  GO.0031974                  Membrane-enclosed lumen                        527              1.44×10^−81^
  GO.0044422                  Organelle part                                 764              1.44×10^−81^
  GO.0070013                  Intracellular organelle lumen                  516              9.85×10^−81^
  GO.0043233                  Organelle lumen                                519              7.00×10^−80^

GO, Gene Ontology; DEGs, differentially expressed genes; FDR, false discovery rate.

###### 

GO Enrichment analysis of downregulated DEGs.

  A, Biological processes                                                                
  --------------------------- ----------------------------------------- ---------------- --------------
  GO.0006955                  Immune response                           264              1.30×10^−72^
  GO.0002376                  Immune system process                     316              1.43×10^−63^
  GO.0006952                  Defense response                          254              4.60×10^−60^
  GO.0007166                  Cell surface receptor signaling pathway   308              1.34×10^−55^
  GO.0045087                  Innate immune response                    188              1.28×10^−49^
                                                                                         
  **B, Molecular function**                                                              
                                                                                         
  **GO ID**                   **Pathway description**                   **Gene count**   **FDR**
                                                                                         
  GO.0005515                  Protein binding                           469              3.99×10^−35^
  GO.0005488                  Binding                                   789              8.01×10^−23^
  GO.0043168                  Anion binding                             262              7.17×10^−14^
  GO.0019899                  Enzyme binding                            156              1.78×10^−13^
  GO.0060089                  Molecular transducer activity             184              5.74×10^−13^
                                                                                         
  **C, Component function**                                                              
                                                                                         
  **GO ID**                   **Pathway description**                   **Gene count**   **FDR**
                                                                                         
  GO.0005829                  Cytosol                                   344              2.76×10^−27^
  GO.0005737                  Cytoplasm                                 761              2.68×10^−22^
  GO.0071944                  Cell periphery                            413              7.57×10^−19^
  GO.0005886                  Plasma membrane                           403              1.46×10^−17^
  GO.0005622                  Intracellular                             884              6.42×10^−14^

GO, Gene Ontology; DEGs, differentially expressed genes; FDR, false discovery rate.

###### 

KEGG pathway analysis of DEGs.

  A, Upregulated                                                        
  ------------------------------------------- ------------------------- --------------
  Metabolic pathways                          197                       1.71×10^−38^
  Huntington\'s disease                       47                        1.58×10^−15^
  Ribosome                                    37                        7.29×10^−14^
  Oxidative phosphorylation                   36                        5.91×10^−13^
  Parkinson\'s disease                        37                        7.94×10^−13^
                                                                        
  **B, Downregulated**                                                  
                                                                        
  **Pathway description**                     **Observed gene count**   **FDR**
                                                                        
  Osteoclast differentiation                  46                        1.66×10^−21^
  Tuberculosis                                53                        6.51×10^−21^
  Chemokine signaling pathway                 53                        4.78×10^−20^
  Natural killer cell-mediated cytotoxicity   43                        2.71×10^−19^
  Influenza A                                 47                        6.17×10^−17^

KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes; FDR, false discovery rate.
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